INVESTOR ALERT: Class Action Lawsuit Against Prosensa Holding N.V. Filed By Glancy Binkow & Goldberg LLP

  INVESTOR ALERT: Class Action Lawsuit Against Prosensa Holding N.V. Filed By
  Glancy Binkow & Goldberg LLP

Business Wire

LOS ANGELES -- July 18, 2014

Glancy Binkow & Goldberg LLP, representing investors of Prosensa Holding N.V.
(“Prosensa” or the “Company”) (NASDAQ:RNA), has filed a class action lawsuit
in the United States District Court for the Southern District of New York on
behalf of a class (the “Class”) comprising all persons and/or entities who
purchased or otherwise acquired the ordinary shares of Prosensa pursuant
and/or traceable to the Registration Statement and Prospectus (collectively,
the “Registration Statement”) issued in connection with the Company’s initial
public offering (“IPO”) on or about June 28, 2013.

Please contact us at (310) 201-9150, or at shareholders@glancylaw.com to
discuss this matter. If you inquire by email, please include your mailing
address, telephone number and number of shares purchased.

Prosensa is a biotechnology company engaged in the discovery and development
of RNA-modulating therapeutics for the treatment of genetic disorders. The
Company’s first and lead product candidate was drisapersen, which Prosensa was
developing in collaboration with GlaxoSmithKline to address a variety of
mutations resulting in inadequate production of dystrophin − a protein
necessary for muscle function. The Complaint alleges that the Registration
Statement contained materially false and/or misleading statements and/or
omitted material information concerning the development status of drisapersen,
the drug’s Phase II and Phase III clinical studies, and the prospects for
drisapersen’s regulatory approval.

On September 20, 2013, less than three months after the IPO, the Company
issued a joint press release with GlaxoSmithKline, disclosing that drisapersen
had not met the primary endpoint in the Phase III study. According to the
press release, “[t]here was no treatment difference in key secondary
assessments of motor function: 10-meter walk/run test, 4-stair climb and North
Star Ambulatory Assessment.”

As a result of this news, Prosensa stock declined approximately 70 percent, or
$16.86 per share, on unusually heavy trading volume, to close on September 20,
2013 at $7.14 per share.

If you are a member of the Class described above, you may move the Court no
later than 60 days from the date of this Notice to serve as lead plaintiff, if
you meet certain legal requirements. To be a member of the Class you need not
take any action at this time; you may retain counsel of your choice or take no
action and remain an absent member of the Class. If you wish to learn more
about this action, or if you have any questions concerning this announcement
or your rights or interests with respect to these matters, please contact
Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park
East, Suite 2100, Los Angeles, California 90067, at (646) 539-8980, by e-mail
to shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email, please include your mailing
address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contact:

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Lesley Portnoy, 646-539-8980
shareholders@glancylaw.com
www.glancylaw.com
 
Press spacebar to pause and continue. Press esc to stop.